Pipeline
MYC Pathway Inhibitor


The Myc oncoprotein is one of the most important but intractable cancer targets. Myc is one of the most frequently deregulated proteins in human cancer and is associated with many types of aggressive tumors. Myc has been known for years to be central to cancer cell proliferation and survival, but it has not been amenable to conventional approaches used in drug discovery. A drug targeting Myc action would be potentially very useful in the treatment of a variety of human cancers. We are currently in the compound selection phase.